Chromogranin A in the Follow-up of Digestive Neuroendocrine Neoplasms: Is It a Useful Biomarker? Abstract #1533

Introduction: Chromogranin A (CgA) is the most frequently used biomarker in digestive neuroendocrine neoplasms (DNENs) but its real usefulness is still unclear
Aim(s): To identify CgA clinical usefulness and the most accurate cut-off to detect disease progression (DP) or recurrence (DR) in the follow-up of DNEN
Materials and methods: Unicenter retrospective analysis of sporadic DNENs with ≥ 24-mos follow-up and ≥2 CgA assessments. Circulating CgA was measured by Cisbio CgA-RIA (Gif-sur-Yvette, France). For clinical usefulness we meant CgA accuracy in detecting DP/DR at least 3 mos before imaging tests, and considered only cases in which CgA was measured before DP/DR. We analyzed CgA accuracy using different CgA changes: increase ≥50% from previous CgA level, increase ≥ 30%, ≥ 2xULN
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: MD, PhD Elettra Merola

To read results and conclusion, please login ...

Further abstracts you may be interested in

#396 Telotristat Etiprate Produces Clinical and Biochemical Responses in Patients with Symptomatic Carcinoid Syndrome: Preliminary Results of an Ongoing Phase 2, Multicenter, Open-label, Serial-ascending, European Study
Introduction: Excess serotonin (5-HT) may cause gastrointestinal (GI) symptoms (e.g., diarrhea) in carcinoid syndrome (CS) patients. Telotristat etiprate is an oral serotonin synthesis inhibitor designed to reduce peripheral 5-HT levels and alleviate GI distress.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Marianne E Pavel
#436 Role of Somatostatin Analogues in the Management of Merkel Cell Carcinoma: A Case Report
Introduction: Merkel cell carcinoma (MCC) is a relatively rare neuroendocrine malignant tumor that is characterized by an aggressive course with regional nodal involvement, distant metastases and a high rate of recurrence.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Kristina Orlova
#498 Limitations of Chromogranin A in Clinical Practice
Introduction: Chromogranin-A (CgA) is the most accurate marker for the histological diagnosis of neuroendocrine tumors (NETs). However diagnostic usefulness of circulating CgA is controversial as several conditions, both neoplastic and non-neoplastic, may induce false positive increases of this marker.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Vincenzo Marotta
#661 Telotristat Etiprate Produces Clinical and Biochemical Responses in Patients with Carcinoid Syndrome: Results of a Phase 2, Multicenter, Open-label, Serial-Ascending Study
Introduction: Excess serotonin (5-HT) in patients (pts) with carcinoid syndrome (CS) is associated with symptoms including increased bowel movement (BM) frequency.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Others
Presenting Author: Marianne Pavel
#642 Correlation Between Chromogranin A and RECIST in Neuroendocrine Tumors’ Treatment
Introduction: High Chromogranin A (CGA) levels have been associated with both tumor burden and the secretory activity of GEPNETs specially carcinoids.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: PhD MD Paula Jimenez Fonseca